Loading...
•
Dec 31, 2020
Amphastar Q4 2020 Earnings Report
Amphastar reported a net revenue of $95.9 million and a GAAP net loss of $6.3 million for the quarter ended December 31, 2020.
Key Takeaways
Amphastar Pharmaceuticals reported a net revenue of $95.9 million for Q4 2020, representing a 15% increase compared to the same period in the previous year. However, the company experienced a GAAP net loss of $6.3 million, or $0.13 per share, though adjusted non-GAAP net income was $8.0 million, or $0.16 per share.
Net revenues for the fourth quarter were $95.9 million.
GAAP net loss for the fourth quarter was $6.3 million, or $0.13 per share.
Adjusted non-GAAP net income for the fourth quarter was $8.0 million, or $0.16 per share.
Glucagon's approval and growth in Primatene Mist and epinephrine sales drove top-line growth in 2020.
Revenue by Segment
Forward Guidance
Amphastar remains optimistic that the trends of growth in Primatene Mist® and epinephrine multi-dose vials sales will continue into 2021 and looks forward to the pipeline’s continued development.
Positive Outlook
- Continued success of nationwide television, radio, and digital marketing campaign for Primatene Mist®
- Increase in distribution channels, including a growth in online sales through Amazon and Kroger
- Higher unit volumes of Enoxaparin as a result of a competitor leaving the market
- Increased Epinephrine sales due to the launch of approved epinephrine injection multi-dose vials
- FDA recognized the Company’s glucagon product as a ‘significant first generic drug approval’ for 2020
Challenges Ahead
- Naloxone sales decreased due to lower average selling price because of increased competition
- Other finished pharmaceutical product sales decreased due to lower demand, largely due to competitors returning to their normal distribution levels
- Increased sales of low margin enoxaparin
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...